Since 2003, the NHF has supported the successful completion of nine studies related to applications such as Bremachlorin-PDT and
Photoimmunotherapy. Many of the studies are described in our publications. For example, the above image shows the patent for Bremachlorin (Radachlorin), a photosensitizer owned by one of our sister companies. Research indicates that, due to its unique blend of three components, Bremachlorin has an excellent safety profile as well as superb efficacy for a range of cancers and infectious diseases.